FY2017 EPS Estimates for OncoMed Pharmaceuticals, Inc. (OMED) Raised by Jefferies Group
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) – Investment analysts at Jefferies Group lifted their FY2017 earnings per share (EPS) estimates for shares of OncoMed Pharmaceuticals in a research report issued to clients and investors on Thursday. Jefferies Group analyst M. Raycroft now expects that the biopharmaceutical company will post earnings per share of ($2.06) for the year, up from their previous estimate of ($2.31). Jefferies Group currently has a “Buy” rating and a $5.00 target price on the stock. Jefferies Group also issued estimates for OncoMed Pharmaceuticals’ FY2018 earnings at ($0.64) EPS, FY2019 earnings at $0.22 EPS, FY2020 earnings at $0.45 EPS and FY2021 earnings at $1.14 EPS.
OncoMed Pharmaceuticals (NASDAQ:OMED) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.10. The business had revenue of $6.20 million during the quarter, compared to analyst estimates of $6.08 million. During the same period in the previous year, the business earned ($0.91) earnings per share. The business’s quarterly revenue was down 7.0% on a year-over-year basis.
COPYRIGHT VIOLATION NOTICE: “FY2017 EPS Estimates for OncoMed Pharmaceuticals, Inc. (OMED) Raised by Jefferies Group” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/09/fy2017-eps-estimates-for-oncomed-pharmaceuticals-inc-omed-raised-by-jefferies-group.html.
Several other equities analysts have also issued reports on the company. JMP Securities lowered OncoMed Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, April 17th. Cantor Fitzgerald lowered OncoMed Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $16.00 to $6.00 in a report on Monday, April 17th. Zacks Investment Research lowered OncoMed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 13th. HC Wainwright reduced their target price on OncoMed Pharmaceuticals from $9.00 to $6.00 and set a “buy” rating for the company in a report on Monday, May 15th. Finally, Piper Jaffray Companies lowered OncoMed Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $17.00 to $5.00 in a report on Monday, April 17th. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $8.00.
OncoMed Pharmaceuticals (NASDAQ OMED) traded down 0.98% during mid-day trading on Monday, hitting $4.05. The stock had a trading volume of 15,513 shares. OncoMed Pharmaceuticals has a 1-year low of $2.91 and a 1-year high of $12.71. The firm’s 50-day moving average price is $3.51 and its 200-day moving average price is $5.82. The stock’s market cap is $150.31 million.
In other news, Director Jack W. Lasersohn acquired 34,614 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were acquired at an average price of $3.37 per share, for a total transaction of $116,649.18. Following the completion of the purchase, the director now owns 185,709 shares in the company, valued at $625,839.33. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jonathan D. Root sold 7,487 shares of the company’s stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $3.70, for a total value of $27,701.90. Following the completion of the transaction, the director now owns 121,020 shares in the company, valued at approximately $447,774. The disclosure for this sale can be found here. In the last quarter, insiders purchased 88,121 shares of company stock worth $304,289. 32.80% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of OMED. American International Group Inc. increased its position in OncoMed Pharmaceuticals by 9.0% in the first quarter. American International Group Inc. now owns 10,977 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 905 shares during the last quarter. KCG Holdings Inc. purchased a new position in OncoMed Pharmaceuticals during the first quarter valued at approximately $103,000. Russell Investments Group Ltd. purchased a new position in OncoMed Pharmaceuticals during the first quarter valued at approximately $141,000. Metropolitan Life Insurance Co. NY purchased a new position in OncoMed Pharmaceuticals during the first quarter valued at approximately $160,000. Finally, Teachers Advisors LLC increased its position in OncoMed Pharmaceuticals by 10.8% in the fourth quarter. Teachers Advisors LLC now owns 30,423 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 2,961 shares during the last quarter. Institutional investors and hedge funds own 44.20% of the company’s stock.
OncoMed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.